The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $97.89

Today's change-4.04 -3.96%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $97.89

Today's change-4.04 -3.96%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Celgene Corp down (U.S.)$4.04

Celgene Corp closed sharply lower Friday, dropping (U.S.)$4.04 or 3.96% to (U.S.)$97.89. Over the last five days, shares have lost 2.42% and are down 18.26% for the last year to date. This security has underperformed the S&P 500 by 9.59% during the last year.

Key company metrics

  • Open(U.S.) $101.72
  • Previous close(U.S.) $101.93
  • High(U.S.) $101.94
  • Low(U.S.) $96.40
  • Bid / Ask(U.S.) $97.47 / (U.S.) $103.35
  • YTD % change-18.26%
  • Volume7,802,222
  • Average volume (10-day)8,178,202
  • Average volume (1-month)7,300,425
  • Average volume (3-month)5,874,675
  • 52-week range(U.S.) $92.98 to (U.S.) $140.72
  • Beta1.27
  • Trailing P/E50.52×
  • P/E 1 year forward17.84×
  • Forward PEG0.80×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.94
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+17.31%

Based on its net profit margin of 17.31%, Celgene Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue2,5632,3342,2782,081
Total other revenue--------
Total revenue2,5632,3342,2782,081
Gross profit2,4582,2242,1771,977
Total cost of revenue105110101104
Total operating expense1,6632,2761,8651,224
Selling / general / administrative609550617529
Research & development7771,3051,110506
Depreciation / amortization88646464
Interest expense (income), net operating--------
Unusual expense (income)84248-2621
Other operating expenses, total--------
Operating income90058412857
Interest income (expense), net non-operating-125-105-64-63
Gain (loss) on sale of assets--------
Other--------
Income before tax746-20471827
Income after tax561-34356719
Income tax, total18514115108
Net income561-34356719
Total adjustments to net income--------
Net income before extra. items561-34356719
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items561-34356719
Inc. avail. to common incl. extra. items561-34356719
Diluted net income561-34356719
Dilution adjustment--------
Diluted weighted average shares817791825834
Diluted EPS excluding extraordinary itemsvalue per share0.69-0.040.430.86
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.760.160.410.88